Bristol University spin-out Apitope develops promising treatment for multiple sclerosis.

Apitope, a life sciences spin-out from Bristol University, has announced a promising new drug for treatment of multiple sclerosis (MS). The drug, which treats the underlying cause of MS, halts progress of the disease, and showed improvements in 43 of the 49 patients treated. Following completition of its Phase I trial, the company has licensed…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.